1. Home
  2. RYAN vs CRSP Comparison

RYAN vs CRSP Comparison

Compare RYAN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryan Specialty Holdings Inc.

RYAN

Ryan Specialty Holdings Inc.

HOLD

Current Price

$35.12

Market Cap

4.1B

Sector

Finance

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$52.61

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYAN
CRSP
Founded
2010
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.9B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
RYAN
CRSP
Price
$35.12
$52.61
Analyst Decision
Buy
Buy
Analyst Count
17
17
Target Price
$50.88
$70.29
AVG Volume (30 Days)
2.3M
1.6M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
1.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,051,126,000.00
$289,590,000.00
Revenue This Year
$15.78
$807.72
Revenue Next Year
$12.49
$172.52
P/E Ratio
$86.72
N/A
Revenue Growth
21.28
9169.85
52 Week Low
$29.28
$43.53
52 Week High
$68.53
$78.48

Technical Indicators

Market Signals
Indicator
RYAN
CRSP
Relative Strength Index (RSI) 59.51 51.47
Support Level $30.48 $50.70
Resistance Level $38.61 $59.61
Average True Range (ATR) 1.54 2.87
MACD 0.45 -0.08
Stochastic Oscillator 83.21 35.47

Price Performance

Historical Comparison
RYAN
CRSP

About RYAN Ryan Specialty Holdings Inc.

Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: